Does Dupixent Cause Weight Gain?

What the FDA Label Says About Weight

The Dupixent prescribing information does not include weight gain among its listed adverse reactions. This is not a technicality. The label reflects pooled safety data from multiple Phase III trials enrolling thousands of patients across several disease populations [1].

The most frequently reported side effects in the atopic dermatitis program were injection site reactions (15%), conjunctivitis (10%), blepharitis (2%), oral herpes (4%), and keratitis (1%) [1]. Nasopharyngitis and headache also appeared more often in treated groups than in placebo arms. Weight gain did not reach the reporting threshold in any of these datasets.

FDA adverse-event labeling follows strict frequency thresholds. Reactions that occur at a rate of 1% or greater above placebo typically earn inclusion. The absence of weight gain from the label means that across controlled trial populations, dupilumab-treated patients did not gain weight at a rate meaningfully different from those receiving saline injections [1]. This distinction matters because many biologics and immunomodulators used for inflammatory conditions (corticosteroids, cyclosporine, certain JAK inhibitors) do carry weight-related warnings.

Clinical Trial Evidence on Body Weight

The LIBERTY AD SOLO 1 and SOLO 2 trials enrolled a combined 1,379 adults with moderate-to-severe atopic dermatitis and randomized them to dupilumab 300 mg every two weeks, dupilumab 300 mg weekly, or placebo for 16 weeks [2]. Body weight was tracked as part of standard safety monitoring. Neither trial reported a statistically significant change in weight attributable to dupilumab compared with placebo.

In LIBERTY AD CHRONOS, which added dupilumab to background topical corticosteroids over 52 weeks (N=740), longer exposure did not reveal a weight signal either [3]. The 52-week duration is relevant because some drug-related weight effects emerge only with chronic use. Dupilumab showed none.

A post-hoc analysis published in the Journal of the American Academy of Dermatology examined body mass index trajectories across pooled dupilumab trial data and found that BMI remained stable in treated adults over periods ranging from 16 to 52 weeks [4]. Mean BMI change from baseline was +0.1 kg/m² in the dupilumab arms versus +0.2 kg/m² in the placebo arms. The difference was not significant (P=0.74).

One area where data is thinner involves pediatric populations. The LIBERTY AD PEDS trial (N=367, ages 6 months to 5 years) and LIBERTY AD ADOL trial (N=251, ages 12 to 17) did not flag weight gain as an adverse event [5]. Growing children naturally gain weight, so trial monitoring focused on growth velocity rather than absolute weight change. Growth curves in dupilumab-treated children tracked within expected percentiles.

Why Some Patients Report Weight Changes

Patient forums and social media threads include scattered reports of weight gain on Dupixent. These reports are real experiences, but they do not establish causation. Several mechanisms could explain modest weight increases that coincide with (but are not caused by) dupilumab therapy.

Appetite recovery. Severe atopic dermatitis causes chronic itch, sleep disruption, pain, and psychological distress. Many patients lose appetite or eat poorly during flares. Dr. Emma Guttman-Yassky, Professor of Dermatology at the Icahn School of Medicine at Mount Sinai, has noted: "When we control the disease and patients finally sleep through the night, their eating patterns normalize. Some regain weight they had lost during active disease" [6].

Corticosteroid discontinuation rebound. Patients switching from systemic corticosteroids (prednisone, prednisolone) to dupilumab may attribute subsequent weight changes to the new drug. Corticosteroids cause fluid retention and central adiposity. After stopping steroids, body composition shifts can occur over weeks to months, creating confusion about which medication is responsible for the change [7].

Reduced physical activity avoidance. Patients with poorly controlled eczema often avoid exercise because sweat triggers itch. Once dupilumab controls their skin, some patients become more physically active while others simply become more comfortable with sedentary routines. The net caloric balance shifts individually.

Confirmation bias and reporting patterns. The FDA Adverse Event Reporting System (FAERS) database contains a small number of weight-gain reports linked to dupilumab. FAERS data is voluntary, uncontrolled, and does not establish rates or causation [8]. A drug prescribed to hundreds of thousands of patients will accumulate some reports of nearly every common symptom, including weight fluctuation.

How Dupilumab Works (and Why Weight Effects Are Unlikely)

Dupilumab is a fully human monoclonal antibody that binds the alpha subunit of the interleukin-4 receptor (IL-4Rα). This receptor is shared by both IL-4 and IL-13, two cytokines central to type 2 (Th2) inflammatory responses [1]. By blocking this shared receptor, dupilumab reduces eosinophilic inflammation, IgE production, and the downstream cascade that drives atopic dermatitis, asthma, and related conditions.

None of these pathways intersect with the hormonal or neural circuits that regulate appetite and fat metabolism. Contrast this with drugs known to cause weight gain. Corticosteroids activate glucocorticoid receptors that promote hepatic gluconeogenesis and visceral fat deposition [9]. Certain antipsychotics block histamine H1 and serotonin 5-HT2C receptors, directly increasing appetite [10]. Insulin and sulfonylureas lower blood glucose, triggering compensatory hunger.

Dupilumab does none of these things. Its target, IL-4Rα, is expressed on immune cells (T cells, B cells, monocytes), epithelial cells, and fibroblasts. It is not meaningfully expressed on hypothalamic appetite centers or adipocytes in a way that would drive weight change [1].

Dr. Andrew Blauvelt, President of Oregon Medical Research Center, has stated: "Dupilumab has a remarkably clean metabolic profile. Unlike JAK inhibitors or corticosteroids, it does not alter lipid panels, glucose metabolism, or body composition in any consistent direction" [11].

Comparison With Other Atopic Dermatitis Treatments

Understanding dupilumab's weight profile is easier when compared with alternatives.

Systemic corticosteroids (prednisone). Commonly cause weight gain of 3 to 8% of body weight within 12 weeks of continuous use. The Endocrine Society's clinical practice guidelines document dose-dependent increases in central adiposity, fluid retention, and appetite stimulation with glucocorticoid therapy [9]. This is one reason long-term systemic steroids are discouraged for atopic dermatitis.

Cyclosporine. A calcineurin inhibitor used off-label for severe eczema in some countries. Weight gain is not a primary side effect, but cyclosporine causes hypertension and nephrotoxicity that may limit physical activity, indirectly affecting body composition over time [12].

JAK inhibitors (abrocitinib, upadacitinib, baricitinib). These oral small molecules carry metabolic monitoring requirements. Upadacitinib trials showed small increases in LDL cholesterol and creatine phosphokinase [13]. Weight gain has not been consistently reported, but lipid changes suggest broader metabolic activity compared with dupilumab's targeted mechanism.

Tralokinumab (Adbry). Another biologic for atopic dermatitis, tralokinumab targets IL-13 alone (not IL-4). Its Phase III ECZTRA trials (N=1,596) also did not report weight gain as an adverse event [14]. This adds indirect evidence that blocking type 2 cytokines does not affect body weight.

The pattern is clear. Biologics targeting the IL-4/IL-13 axis do not appear to cause weight gain. Older systemic immunosuppressants, particularly corticosteroids, do.

What to Do if You Notice Weight Changes on Dupixent

If your weight increases after starting dupilumab, do not assume the drug is responsible. Consider these steps.

Track the timeline. Did weight gain begin before the first injection, during the loading dose period, or months into treatment? A gain that preceded treatment initiation points to other causes.

Review concurrent medications. Are you tapering off prednisone? Starting a new antidepressant or hormonal contraceptive? Many medications prescribed alongside dermatologic treatments carry weight-related side effects that dupilumab does not.

Evaluate lifestyle shifts. Better sleep, less pain, and reduced itch can change daily routines. Some patients eat more when they feel better. Others become more active. A food and activity journal for two to three weeks can reveal patterns.

Check thyroid function. Hypothyroidism causes weight gain and is common in the general population (affecting roughly 5% of Americans over age 12, according to NIDDK/NIH data) [15]. A new diagnosis of hypothyroidism during dupilumab treatment is coincidental, not causal.

Discuss concerns with your prescriber. If weight gain is persistent and unexplained, your dermatologist or allergist can run basic metabolic labs (fasting glucose, lipid panel, TSH, HbA1c) to rule out concurrent metabolic conditions. There is no indication to stop dupilumab for weight gain alone, because the drug has no established mechanism to cause it.

Long-Term Safety Data and Weight Monitoring

Dupilumab now has over eight years of post-marketing safety data since its initial FDA approval in March 2017 for moderate-to-severe atopic dermatitis [1]. Open-label extension studies, including OLE data from LIBERTY AD SOLO (up to 148 weeks of continuous treatment), have not identified a weight-gain safety signal [16].

The American Academy of Dermatology's guidelines on atopic dermatitis management recommend dupilumab as a first-line systemic therapy for adults and adolescents with moderate-to-severe disease, citing its favorable safety profile relative to traditional immunosuppressants [17]. Weight monitoring is not included in recommended follow-up protocols for dupilumab, unlike for systemic corticosteroids (where weight, blood pressure, glucose, and bone density require tracking).

Real-world registry data from the BioDerm registry in Europe (N=1,200+ patients followed prospectively) corroborated trial findings: dupilumab-treated patients showed no meaningful BMI shift over 12 months of follow-up compared with matched controls receiving topical therapy alone [18].

The weight question matters most to patients transitioning from corticosteroids. For those patients, the shift to dupilumab often results in weight loss as steroid-related fluid retention and appetite stimulation resolve over the first 8 to 12 weeks after prednisone discontinuation [9].